Innovent Biologics: Sintilimab Receives Positive CHMP Opinion Recommending Approval for First-Line Treatment of Non-Squamous Non-Small Cell Lung Cancer
Innovent Biologics announced that its sintilimab has received the first positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP), which recommends approval of the marketing authorization for sintilimab in combination with chemotherapy for adult patients with advanced non-squamous non-small cell lung cancer. The recommendation is based on results from the Phase III ORIENT-11 study, in which sintilimab in combination with chemotherapy reduced the risk of disease progression or death by 52% and the risk of death by 35%. The European Commission is expected to make a final decision on the marketing authorization in the coming months.
Latest

